Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUBP1 | Q96AE4 | 6/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 0.76 |
| ▸ | MAPT | P10636 | 9/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | CASP1 | P29466 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21436681 | 1.00 | FUBP1 (1.00) | FUBP1TP53MAPTTDP1MAPK1 | |
| SCHEMBL30417906 | 0.88 | FUBP1 (1.00) | FUBP1TP53MAPTTDP1MAPK1 | |
| SCHEMBL21436605 | 0.88 | FUBP1 (1.00) | FUBP1TP53MAPTTDP1MAPK1 | |
| SCHEMBL21436636 | 0.84 | FUBP1 (1.00) | FUBP1TP53MAPTTDP1MAPK1 | |
| SCHEMBL15559690 | 0.82 | TP53 (0.79) | FUBP1TP53MAPTTDP1MAPK1 | |
| SCHEMBL17066235 | 0.80 | MAPT (0.75) | FUBP1TP53MAPTTDP1MAPK1 | |
| SCHEMBL17066234 | 0.80 | FUBP1 (0.79) | FUBP1TP53MAPTTDP1MAPK1 | |
| SCHEMBL21945408 | 0.80 | FUBP1 (0.79) | FUBP1TP53MAPTTDP1MAPK1 | |
| SCHEMBL17066232 | 0.79 | MAPT (0.73) | FUBP1TP53MAPTTDP1MAPK1 | |
| SCHEMBL17066463 | 0.79 | MAPT (0.77) | FUBP1TP53MAPTTDP1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409939-A1 | COMBINATION OF OLIGONUCLEOTIDES FOR MODULATING RTEL1 AND FUBP1 | HOFFMANN-LA ROCHE INC. | 2024-12-12 | — | — | US | disclosed |
| CN-119095603-A | Combinations of oligonucleotides for modulating RTEL1 and FUBP1 | 豪夫迈·罗氏有限公司 | 2024-12-06 | — | — | CN | disclosed |
| EP-4448106-A1 | COMBINATION OF OLIGONUCLEOTIDES FOR MODULATING RTEL1 AND FUBP1 | Hoffmann-La Roche Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023111210-A1 | COMBINATION OF OLIGONUCLEOTIDES FOR MODULATING RTEL1 AND FUBP1 | F. HOFFMANN-LA ROCHE AG (CH) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409939-A1 | COMBINATION OF OLIGONUCLEOTIDES FOR MODULATING RTEL1 AND FUBP1 | FUBP1, TERF2IP, FUBP3 | FUBP1 1/4885TP53 899/4885MAPT 2683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.